antagonists include dizziness, headache, and diarrhea or constipation.
They are not associated with sedation or extrapyramidal symptoms (EPS). 5-HT3 may also cause asymptomatic electrocardiogram changes including prolonged PT and QTc intervals.
Corticosteroids
Methylprednisone (MP) and dexamethasone are recommended for prevention of acute CINV for low and moderately emetogenic chemotherapy. 35 The mechanism underlying corticosteroid efficacy is unknown; however, it is hypothesized that MP decreases cisplatininduced 5-HT release from peripheral blood mononuclear cells. 36 In early studies, dexamethasone was shown to be superior to metoclopramide in patients receiving non-platinum-based regimens. 37 Previously, 5HT3 
Substance P Inhibitors
Aprepitant is an oral regimen for the prevention of acute and delayed nausea and vomiting that works by binding to the protachykinin-1 receptor. Protachykinin-1, a mediator of pain, inflammation, nausea, and vomiting, cannot bind to aprepitant-occupied receptors. 39 Other protachykinin-1 receptor antagonists include 298, vofopitant, 721, 974 ; however, aprepitant is the only clinically available drug. Aprepitant is an oral regimen that is recommended for a three-day course, and has been shown to control cisplatin CINV in the acute and delayed phase in two randomized, placebo-controlled phase III studies. 40, 41 These trials studied 1,099 patients who received 70mg/m 2 cisplatin and who were randomized to receive ondansetron and oral dexamethasone followed by oral dexamethasone twice daily on days two to four after chemotherapy versus aprepitant before chemotherapy followed by aprepitant and dexamethasone daily on days two and three followed by dexamethasone on day four. Several small trials and reviews have attempted to discern the effectiveness of cannabinoids; however, their effectiveness in controlling CINV remains questionable.
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Benzodiazepines
Benzodiazepines can be useful to reduce anxiety and risk of anticipatory CINV. The anti-emetic potential of lorazepam and alprazolam is low; however, they are recommended by MASCC guidelines as they may decrease anticipatory nausea and vomiting.
Benzodiazipines have been shown to decrease anticipatory nausea and vomiting from 18 to 0% in a double-blind, placebo-controlled study of women with breast cancer.
28
Antihistamines Antihistamines such as diphenhydramine or hydroxyzine have been used to treat emesis related to motion sickness. High levels of H1 and muscarinic receptors in neuronal pathways associated with CINV suggest that antihistamines may be effective; however, their role is poorly defined in treating CINV.
7
Phenothiazines
Prochlorperazine and thiopropanate were the first drugs found to be superior to placebo in reducing CINV.
52
The effectiveness of phenothiazines is dose-related, and this class of anti-emetic is limited by antidopaminergic side effects of hypotension, restlessness, EPS, and sedation. Concurrent use of phenothiazine, substituted benzamide, and butyrophenone is advised against because of increased risk for movement disorders, including akathisia and EPS.
Butyrophenones
Haloperidol, droperidol, and domperidone have anti-emetic activity by blocking dopamine receptors. The butyrophenones are considered relatively ineffective in treating CINV.
53,54
Atypical Antipsychotics Highly Emetogenic Chemotherapy ASCO, NCCN, and MASCC guidelines all recommend 5HT3-antagonist, dexamethasone, and aprepitant within the first 24 hours for prevention of acute CINV caused by highly emetogenic chemotherapy.
17-19
Recommendation for treatment of delayed CINV caused by highly emetogenic chemotherapy includes dexamethasone and aprepitant. In a meta-analysis, which did not include palonosetron, 5HT3 antagonists
were not cost-effective in preventing delayed CINV from highly emetogenic chemotherapy. 
Mildly Emetogenic Chemotherapy
Single-agent anti-emetics may be used for prophylaxis of mildly emetogenic chemotherapies. MASCC and ASCO guidelines advise single-agent dexamethasone, while NCCN also recommends prochloperazine or metoclopramide as alternatives. 
Treatment of Breakthrough and Refractory Nausea and Vomiting
Innovations in Treatment Delivery
Barriers to prevention of CINV, including the impracticality of oral medication for a patient who is already nauseated, difficulty 
Alternative Therapies
Randomized trials have attempted to explore non-pharmacological interventions for CINV. Yoga, hypnosis, acupressure, acupuncture-point stimulation, and massage therapy have been shown to have some benefit. 63-67 Although pre-chemotherapy patient education can reduce nausea expectancy, it has no effect on the occurrence of nausea.
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Anti-emetics in Children
There are limited data regarding utilization, timing, and dosages appropriate for prophylaxis of CINV in children. 5HT3 antagonists have been shown to be more effective than metoclopramide, phenothiazone, and cannabinoids. 69 The few studies that examine anti-emetics in children receiving chemotherapy have small numbers and suboptimal design. 
Future Research Directions
